Novo Nordisk (NVO) shares are falling in Wednesday's pre-market session — and into the regular trading session — after the pharmaceutical giant missed second quarter revenue estimates ($3.8 billion vs. expectations of $4.1 billion) tied to Wegovy sales.

Senior health reporter Anjalee Khemlani interviews Novo Nordisk CFO Karsten Munk Knudsen, who discusses the sales figures for its landmark weight-loss drug and calling Wall Street's reaction "a blip."

"For the second quarter, we're growing the company 25% in the first half, which is top end of the industry. And, and we raised our full year outlook, top line wise, also by a couple of percentage points," Knudsen says. "Right now, demand is greater than supply for Wegovy and overall for the obesity market given the significant unmet need. We are scaling Wegovy as we speak already, significantly."

When asked about whether Novo Nordisk is considering licensing its GLP-1 products to expedite US access to them, Knudsen asserted the company is already "maxing out in terms of supply... we are really supplying as much as we are able to produce."

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Luke Carberry Mogan.